All In MedTech

FDA Clearance Tracker · P950027-S004

HYALGAN

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 30, 2000 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 30, 2000

Approved

Time to decision

616 days

Received Dec 23, 1998. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P950027-S004
Device name
HYALGAN
Applicant location
Abano Terme
Received
Dec 23, 1998
Decided
Aug 30, 2000
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P950027

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL TO MODIFY LABELING, ADDING INFORMATION ABOUT THE CURRENT CLINICAL EXPERIENCE OF THE DEVICE.

Source documents

Other decisions for Fidia Farmaceutici S.P.A.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.